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FOCuS: IMMuNOLOGY AND IMMuNOTHERAPEuTICS
cancer immunotherapy takes a Multi-Faceted
Approach to Kick the immune System into
Gear
Peniel M. Dimberu and Ralf M. Leonhardt
Department of Immunobiology, Yale School of Medicine, New Haven, Connecticut
Cancer accounts for about every fourth death in the united States, with approximately 1,500
people dying each day as a result of this disease. Despite some progress in the last
decades, these numbers alone undoubtedly demonstrate the urgent need for new and more
efficient treatments. Immunotherapy aims to activate an efficient immune response against
tumors or even prevent cancers from occurring in the first place. It is a growing field currently
flourishing with several successful trials, some of which have led to the recent approval of
new anti-cancer drugs by the Food and Drug Administration (FDA†). This review addresses
the manifold strategies that immunotherapy has taken in the past and discusses the most
recent achievements in the field.
introduction
With about 7.6 million cancer deaths
worldwide  in  2008  [1]  and  more  than
570,000 cancer deaths projected to occur in
2011 in the United States alone (>1500
deaths per day) [2], cancer is clearly one of
the most pressing health problems we face
today. Although surgery, radiation therapy,
and chemotherapy have been significantly
improved over the past years [3], metasta-
tic disease can rarely be controlled by these
treatments  and  cures  remain  scarce  [4].
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tute Fellowship. Promising recent developments suggest that
cancer immunotherapy ― modulating the
immune system to target the cancer ― may
become a powerful new weapon in the arse-
nal of treatments that oncologists can offer
patients. Immunotherapy offers several ad-
vantages to today’s standard treatments. Ac-
tivated and tumor-specific immune cells can
reach areas that a surgeon cannot, and the
immune system may, when appropriately
stimulated, target even microscopic disease
and disseminated metastases. Further, im-
munotherapy does not preferentially attack
dividing tumor cells, as chemotherapy and
radiation therapy usually do. Thus, cancer
cells that are slowly dividing or quiescent ―
properties many believe are associated with
cancer stem cells [5] ― might be more effi-
ciently  targeted  by  immunotherapy.  De-
pending on the approach, immunotherapy
might strike more specifically against the
tumor, thus lowering the damage to sur-
rounding healthy tissue and preventing de-
bilitating  side  effects  that  are  nearly
unavoidable with radiation and chemother-
apy. It should nevertheless be noted that se-
vere toxicity can be associated with some
particular immunotherapies, such as sys-
temic cytokine treatment [6] or immunoreg-
ulatory  therapy  using  anti-CTLA4
antibodies [7] (as discussed later). Finally,
memory cells can suppress the re-emergence
of the cancer. Long-term control or even
complete eradication of the disease is possi-
bly the biggest promise that immunotherapy
holds for the future, as induced anti-tumor
responses have sometimes proven durable
over many years, at least in a subset of pa-
tients [8]. This contrasts sharply with what is
all too frequently observed with chemother-
apy and radiation therapy, whose effect is
often only temporary and eventually results
in multidrug resistance [9].  
The  origins  of  immunotherapy  may
date back as far as 1774, when a Parisian
physician injected pus into the leg of a pa-
tient with advanced breast cancer and sub-
sequently observed tumor regression as the
infection worsened [4]. Today, novel im-
munotherapies strike far more specifically
and in a more sophisticated manner against
cancers by targeting tumors through indi-
vidual  tumor  antigens  or  disarming  the
tumor’s defense strategies. Several recent
immunotherapeutic trials demonstrate the
impressive clinical benefit of many of these
new treatments even for end-stage patients,
raising hopes that the intensive research of
immunologists worldwide is eventually pay-
ing off by delivering substantial progress in
the fight against cancer.  
MHc clASS i-MediAted AntiGen
preSentAtion ― How tuMorS
betrAy tHeir preSence
Human cells constantly break down a
fraction of their protein content, and some
of the resulting peptides get translocated into
the endoplasmic reticulum (ER) via the pep-
tide transporter TAP. There they are loaded
onto MHC class I molecules (MHC I) within
the peptide-loading complex organized by
the chaperone tapasin [10]. Upon binding a
suitable  ligand,  MHC  I  dissociates  from
tapasin and migrates to the plasma mem-
brane for display of its antigen to cytotoxic
T cells (CTLs). Along the secretory route,
some peptide exchange may occur, if the
original cargo proves suboptimal [11]. A
typical  human  cell  might  well  present
>10,000 peptides to CTLs at steady-state
[12], thus reflecting a representative sample
of the current cellular repertoire of proteins.
If CTLs detect antigens of non-self origin
displayed in the context of MHC I, they will
attack and kill the presenting cell and secrete
cytokines like interferon-γ that further aug-
ment MHC I-mediated antigen presentation.
Killing  by  CTLs  is  typically  achieved
through release of perforin/granzyme-con-
taining cytolytic granules or through the
Fas-FasL pathway ― processes that induce
target  cell  apoptosis  [13].  Critical  tumor
antigens include cancer testis antigens (e.g.,
MAGE family genes or NY-ESO-1), anti-
gens derived from melanocyte differentia-
tion  factors  (e.g.,  gp100,  MART1  or
tyrosinase), antigens encoded by mutated
genes (e.g., oncogene-derived antigens), or
antigens derived from proteins that are over-
expressed in the tumor (e.g., HER2/Neu)
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only  expressed  in  male  germline  cells,
which lack surface MHC I. Hence, their
presentation in tumor cells, typically result-
ing from altered DNA methylation in vari-
ous cancers, is truly tumor specific. This
makes them not only useful as promising
biomarkers [15], but this property also may
be critical in the context of immunotherapy.
Thus, induction of autoimmunity may be
avoided by vaccination with peptides whose
expression  is  strictly  confined  to  cancer
cells. Nevertheless, some of the most suc-
cessful peptide vaccines are derived from
melanocyte differentiation factors (g209-
2M,  derived  from  gp100,  is  discussed
below). Mutated antigens typically have the
disadvantage that they are unique to a par-
ticular patient and thus cannot be broadly
applied in immunotherapy.
A comprehensive database providing in-
formation on tumor antigens presented by
MHC  I  or  MHC  II  can  be  found  at
http://www.cancerimmunity.org/peptidedata-
base/Tcellepitopes.htm.
coMMon MecHAniSMS oF iMMune
evASion by cAncerS ― How tHe
cAncer StriKeS bAcK
Not surprisingly, tumor cells block the
MHC I pathway at practically every possible
step in order to evade an efficient immune
response. For instance, down-regulation or
even complete elimination of expression of
TAP  and  tapasin  are  very  frequently  ob-
served in tumors of diverse tissue origins
[16]. Partial or complete loss of individual
MHC I alleles, whole HLA haplotypes, or β2-
microglobulin (β2m), an essential structural
component of the MHC I molecule, are also
sometimes found. Moreover, the interferon-
γ induction pathway is often impaired in can-
cer cells [17]. All these measures cause a
drop or even a complete collapse of MHC I
surface levels and thus render specific CTLs
unable to identify and attack their targets. As
a backup mechanism, the immune system
may then utilize natural killer (NK) cells,
which  are  particularly  designed  to  track
down and kill surface MHC I-deficient tu-
mors. Cancer cells, however, frequently at-
tempt to abrogate NK cell-mediated killing
in a variety of ways, including upregulation
of  molecules  related  to  MHC  I,  such  as
HLA-E [18], shedding of NK cell activating
ligands, or inhibitory cytokine release [19].
Many tumors also induce factors that directly
or indirectly block potentially attacking T
cells and NK cells in the tumor microenvi-
ronment like IDO or TGF-β [20]. IDO is a
particularly  interesting  molecule,  since  it
breaks down tryptophan into kynurenines
and thereby counteracts T cells by starving
them for this essential amino acid [21], while
kynurenines additionally cause downregula-
tion of activating NK cell receptors [22] and
further inhibit T cells. Further, tumors fre-
quently recruit regulatory T cells (Tregs) or
myeloid suppressor cells that abrogate effi-
cient T cell responses and induce a niche of
tolerance allowing the cancer to grow unim-
peded [20]. TGF-β might be one of the fac-
tors that play a key role in establishing a
favorable protective tumor microenviron-
ment, as this cytokine can induce the differ-
entiation of Tregs. TGF-β may additionally
have a direct suppressive effect on CTLs, by
downregulating critical effector molecules
such as perforin, granzymes, FasL or inter-
feron-γ [20].
tuMor iMMune evASion And tHe
outcoMe oF Anti-cAncer 
iMMunotHerApy
The particular immune evasion strategy
that an individual tumor adopts may deter-
mine whether and how it is going to respond
to immunotherapy. Heterogeneity within a
tumor or among different metastases can
even lead to disparate responses within the
same patient, with some lesions disappear-
ing while at other sites disease progresses.
Cancers displaying irreversible structural
defects like HLA-haplotype loss or deleteri-
ous mutations in β2m may be more difficult
or  impossible  to  target  by  some  im-
munotherapies, while tumors with reversible
defects like TAP downregulation, which can
often be restored by cytokines, may be more
sensitive to these approaches [17]. Future
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and  efficient  immunotherapy  treatments
may have to be tailored according to specific
tumor phenotypes rather than to offer “one
size fits all” solutions.
HiGH-doSe il-2 treAtMent And itS
inteGrAtion witH vAccinAtion
And Adoptive t cell trAnSFer
tHerApy
Melanoma is a particularly immuno-
genic cancer, and many of its typical tumor
antigens are known and have been exten-
sively characterized. Also, melanoma is one
of the deadliest types of cancer with grim 5-
year survival rates of about 16 percent for pa-
tients  with  metastasis  [2].  While
chemotherapy gives very poor results [23],
immunotherapy  has  been  emerging  as  a
promising novel approach. In order to induce
or enhance a patient’s anti-tumor immune re-
sponse, immunostimulatory cytokine treat-
ment  was  considered  early  on,  although
severe toxicity often posed limits to this strat-
egy. Interleukin-2 (IL-2), a growth factor for
lymphocytes  like  T  cells  and  NK  cells,
proved particularly interesting and its toxic-
ity appears to be manageable in many pa-
tients  [24].  Although  high-dose  IL-2
produced tumor regressions qualified as an
objective response in only about 13 percent
to 17 percent of patients, unlike what is typ-
ically observed with chemotherapy, these re-
sponses proved durable in a subset of cases
[8]. Based on this remarkable property, in
1998, the Food and Drug Administration
(FDA) approved this cytokine as the first im-
munotherapy for metastatic melanoma. 
Researchers have since sought to en-
hance the effect of IL-2, for instance by
combining cytokine treatment with vaccina-
tion against tumor antigens. A number of
different vaccines and vaccination strategies
have been tested in patients, including DNA
vaccination, peptide vaccination, vaccina-
tion with tumor lysates, viral transfer of anti-
gens, or antigen delivery via dendritic cells
[8]. A vaccine that proved particularly po-
tent and superior over other vaccines in this
context is g209-2M [24], a peptide based on
an immunodominant epitope derived from
the tumor antigen gp100. Strikingly, in a re-
cent phase III trial, roughly three times more
objective  responses  were  observed  in
metastatic melanoma patients who had re-
ceived this vaccine plus IL-2 versus those
who had received IL-2 alone. Also progres-
sion-free survival was extended, and there
was a trend toward longer overall survival
in vaccine-treated patients [25]. 
Another powerful new tool in the reper-
toire  of  immunotherapeutic  strategies  is
Adoptive Cell Therapy (ACT). In ACT, T
cells are isolated from cancer patients and
stimulated  with  tumor-antigen  presenting
cells  ex  vivo,  before  clones  selected  for
strong anti-tumor immunity are massively
expanded and infused back into the same in-
dividual [8]. Before transfer of the cells, pa-
tients typically undergo non-myeloablative,
lymphodepleting preconditioning in order to
eliminate immunosuppressive regulatory T
cells and non-tumor specific bystander T
cells, which might otherwise compete with
the freshly transferred cells for cytokines. A
further recent development of ACT even in-
cludes the option of genetically modifying T
cells before transfer in order to drive the ex-
pression of selected high-affinity T cell re-
ceptors (TCRs). This might be particularly
helpful  if  patients  have  no  pre-existing
tumor-reactive T cells. In 2006, researchers
engineered patients’ T cells to express a TCR
targeted against the tumor antigen MART1.
After reinfusion of those cells, some indi-
viduals indeed demonstrated sustained ob-
jective regressions of their melanoma [26].
Another alternative is to specifically isolate
tumor-infiltrating lymphocytes and use those
for ACT. Rates of objective tumor regression
with this protocol have reached impressive
percentages of 49 percent to 72 percent, with
some  patients  achieving  complete  and
durable responses [27]. 
tArGetinG iMMunoModulAtory
MoleculeS to enHAnce 
Anti-tuMor reSponSeS
The  new  “rising  star”  in  melanoma
therapy, however, is an antibody called ipil-
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hibitory  receptor  CTLA-4  on  T  cells.
CTLA-4  counteracts  the  activation  of  T
cells, blocks their proliferation and IL-2 re-
lease, and thereby suppresses immune re-
sponses [28]. The molecule is critical for
establishing peripheral self-tolerance and
avoiding autoreactivity, but tumors exploit
this characteristic relentlessly in order to
fend off immune attack. Ipilimumab binds
and blocks CTLA-4, and thereby augments
T-cell mediated immunity. In a recent phase
III trial, median overall survival was 6.4
months in patients receiving the gp100 vac-
cine alone, but it was 10 months in patients
receiving ipilimumab along with the vaccine
and 10.1 months in patients receiving treat-
ment with ipilimumab alone [29]. In fact, it
was  the  first  randomized  clinical  trial
demonstrating a statistically significant ben-
efit  on  overall  survival  in  metastatic
melanoma patients [29]. This remarkable
success prompted the FDA in 2011 to ap-
prove ipilimumab for treatment of metasta-
tic melanoma ― more than a decade after
the last “new” drug for this cancer, IL-2, had
been approved. Most importantly, a recent
phase III trial comparing ipilimumab in con-
junction  with  chemotherapy  against
chemotherapy plus placebo corroborated the
striking clinical benefit of CTLA-4 block-
ade by significantly extending overall sur-
vival and causing higher survival rates in the
group  of  ipilimumab-treated  patients.  In
fact, after 3 years, almost twice as many pa-
tients in the ipilimumab-treated group were
alive than in the control group [30]. More-
over, a combination of ipilimumab and IL-2
therapy may prove synergistic in achieving
an even higher complete response rate [31].
Besides  CTLA-4,  there  are  other  im-
munoregulatory molecules that future thera-
pies might target like PD-1 or IDO. PD-1 is
also an inhibitory receptor expressed on T
cells, and tumors frequently express its lig-
and, PD-L1, in order to abrogate cytotoxic
T cell activity. Recent trials suggest that tar-
geting PD-1 might have very similar clini-
cal potential like targeting CTLA-4 [32].
Judging from all the above, it might be a
safe guess that disarming defense strategies
of tumors will be a cornerstone of future
anti-cancer immunotherapies.
StAyinG AHeAd oF cAncer ―
StriKinG witH preventive 
vAccineS
Attempts to create vaccinations against
cancer have taken many forms. One ap-
proach has been to vaccinate against viruses
that increase the chances of developing can-
cer. The very first such vaccine was the hep-
atitis B virus (HBV) vaccine approved by
the FDA in 1981 and is now part of the
schedule of vaccines given to infants. The
widespread use of this vaccine has dramati-
cally reduced the rates of HBV infection and
hepatocellular carcinoma (HCC). The most
compelling data comes from a comparison
of vaccinated and unvaccinated birth cohorts
in a 20-year follow-up study of a universal
vaccination program in Taiwan [33]. The
study found an incidence rate of 0.57 per
100,000 person-years in those born before
the start of the vaccination program but an
incidence rate of 0.17 in those born after its
start. Further, it was found that this dramatic
decrease in HCC rates continued well into
the adulthood of those vaccinated at an early
age [33]. Another such preventive vaccine
has been developed against human papillo-
mavirus (HPV), which is responsible for
causing virtually all cases of cervical cancer.
Two well-known HPV vaccines that have
made  it  to  market  in  recent  years  are
Merck’s Gardasilﾮ and GlaxoSmithKline’s
Cervarixﾮ. Both vaccines target HPV types
16 and 18, which are responsible for more
than 70 percent of cervical cancer cases
(Gardasilﾮ also targets types 6 and 11, which
contribute to virtually all cases of genital
warts) [34]. 
Today, researchers have identified sev-
eral other viruses that are classified as being
carcinogenic [35]. This includes hepatitis C
virus (HCV), which, similar to HBV, can
lead to hepatocellular carcinoma. Epstein-
Barr virus is also implicated in several types
of  lymphomas  and  human  immunodefi-
ciency virus 1 (HIV-1) infection that can
lead to Kaposi sarcoma. Currently, there are
375 Dimberu and Leonhardt: Cancer immunotherapyno vaccines against these pathogens. How-
ever, it is likely that the development of an
effective vaccine would indeed lower rates
of cancer associated with these viruses.
novel tHerApeutic vAccineS
AiM to ActivAte iMMune 
reSponSeS AGAinSt eStAbliSHed
tuMorS
In contrast to preventive vaccines, thera-
peutic vaccines attempt to coax the patient’s
immune system to respond to an existing can-
cer. The most promising new vaccines in this
area are autologous tumor vaccines, in which
antigen-presenting cells (APCs) are isolated
from a patient and then cultured in the pres-
ence of a cancer antigen before being infused
back into the patient. At this point, the APCs
can present the antigen to cytotoxic T cells and
activate them to attack the tumor. The first
such vaccine to come to market is Sipuleucel-
T  (Provengeﾮ),  which  targets  advanced,
metastatic prostate cancer and was approved
by the FDA in April 2010. Sipuleucel-T is cre-
ated by exposing a patient’s dendritic cells to
a fusion protein that is composed of prostatic
acid phosphatase (an antigen found in 95 per-
cent of prostate cancers) and granulocyte-
macrophage  colony-stimulating  factor
(GM-CSF) before reinfusion. Clinical trials in
men who were unresponsive to androgen-de-
privation therapy demonstrated an increase in
median survival of 4.1 months compared to
placebo (25.8 vs. 21.7 months). Further, 36-
month  survival  rates  for  the  Sipuleucel-T
group were 31.7 percent compared to 23.0
percent in the control group [36]. 
Another autologous vaccine that has
had strong Phase III clinical trial results is
BiovaxIDﾮ, created against follicular non-
Hodgkin lymphoma. BiovaxIDﾮ is created
using a novel approach known as rescue fu-
sion hybridization, where a tumor cell is
fused to an antibody-secreting cell. This hy-
bridoma then secretes a unique idiotype anti-
gen that is unique to the tumor and can be
injected into the patient to elicit an immune
response. In patients who had experienced
chemotherapy-induced remission of longer
than 6 months, vaccination with BiovaxIDﾮ
resulted in maintenance of remission for
44.2 months compared to the 30.6 months in
the control group [37]. 
Despite the success of these vaccines,
caveats that need to be addressed remain.
One aspect that currently limits the further
development of autologous tumor vaccines
is selection of an appropriate antigen to tar-
get. While some antigens are unique to a
tumor, often they are similar to those found
on healthy cells and thus could result in ad-
verse side effects. Further, some tumors ex-
hibit  great  diversity  in  the  antigens  that
could be targeted, rendering ineffective any
vaccine that only targets one or two anti-
gens. And the more antigens that need to be
targeted, the more complex and difficult it
becomes to develop a truly efficacious treat-
ment.  Therefore,  cancers  that  express  a
unique and limited number of antigens are
likely to be more susceptible to this ap-
proach.
MonoclonAl Antibody 
treAtMentS deSiGned to 
tArGet And blocK MoleculeS
eSSentiAl For tuMor 
developMent/SurvivAl
Eleven years after Georges K￶hler and
C￩sar Milstein developed hybridoma tech-
nology to produce monoclonal antibodies,
the first therapeutic product was approved to
treat transplant rejection in 1986. It took an-
other 11 years before a monoclonal antibody
therapy against cancer was developed. Rit-
uximab (Rituxanﾮ), which targets the B-cell
marker CD20, was approved in the United
States in 1997 and has found widespread use
in not only treating B cell malignancies, but
also B cell-mediated autoimmune disorders.
This is particularly the case with rheumatoid
arthritis, for which rituximab was FDA-ap-
proved in 2006 [38]. Although rituximab tar-
gets both normal and dysfunctional B cells,
studies have found that patients treated with
it do not exhibit an increased susceptibility
to infection [39].
Today, monoclonal antibody treatments
for cancer represent some of the most suc-
cessful  cancer  immunotherapies.  These
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that cancer cells utilize for their survival and
proliferation.  For  example,  trastuzumab
(Herceptinﾮ),  used  in  HER2-expressing
breast cancer, facilitates downregulation of
the HER2 receptor (overexpressed in about
30 percent of breast cancer cases) and in-
duces antibody-dependent cell-mediated cy-
totoxicity (ADCC). Further, bevacizumab
(Avastinﾮ) binds and prevents the function
of  the  angiogenic  vascular  endothelial
growth factor (VEGF), whereas cetuximab
(Erbituxﾮ) binds to the epidermal growth
factor receptor (EGFR). Despite their vari-
ous mechanisms of action, all of these drugs
have become part of the standard treatment
protocol, in combination with chemotherapy
and/or radiation [40], and for good reason as
these drugs have been demonstrated to be ef-
fective  in  patients.  For  instance,  clinical
studies that compared chemotherapy alone
with a combination of chemotherapy and
trastuzumab found that combination therapy
slowed disease progression, increased re-
sponse rates, and increased median survival
rates by 25 percent [41]. 
Bevacizumab was initially investigated
and approved for use against colorectal can-
cer after clinical studies demonstrated an in-
crease in median survival of 20.3 months
compared to 15.6 months in the control group
[42]. However, it has recently been found to
be effective against several other cancers, in-
cluding recurring glioblastoma multiforme,
for which it received FDA approval in 2009
[43]. Cetuximab is another antibody that was
initially approved for use against metastatic
colorectal cancers, in which EGFR overex-
pression is found in as much as 80 percent of
cases [44]. Another mutation common in col-
orectal cancers is that of the proto-oncogene
KRAS, found in approximately 40 percent of
cases. Clinical studies involving cetuximab
found that patients with the KRAS mutation
did not respond to this antibody treatment and
current guidelines call for cetuximab’s use in
KRAS-wild type patients only [45]. More re-
cently, cetuximab was approved for use in
squamous cell carcinoma of the head and
neck.  Long-term  follow-up  studies  have
found a 45.6 percent 5-year survival rate
when cetuximab is combined with radiation
therapy, compared with a rate of 36.4 percent
when radiation is used alone [46]. 
rAdioiMMunotHerApy ― SeeK
And deStroy
Radioimmunotherapy is a treatment that
involves conjugating a radionuclide to an an-
tibody  that  targets  cancer  antigens.  The
specificity of the antibody targets the toxic
radionuclide to the cancer cells with minimal
damage to healthy cells. Currently, there are
two FDA-approved drugs on the market, 90Y-
ibritumomab tiuxetan (Zevalinﾮ) and  131I-
tositumomab, both of which are used against
B-cell malignancies [47]. Ibritumomab tiux-
etan is an IgG1 anti-CD20 antibody conju-
gated with 90Y and is used to mainly treat
non-Hodgkin lymphoma. In clinical trials
that compared it to rituximab, it was demon-
strated that ibritumomab elicited a higher re-
sponse rate compared to rituximab alone (80
percent vs. 56 percent) [48]. Ibritumomab
has also been shown to slow the progression
of disease in patients experiencing a relapse,
including those who had a strong initial re-
sponse to rituximab treatment [48]. 
Similarly, 131I-tositumomab is an IgG2a
anti-CD20 antibody used to treat refractory or
relapsed, low-grade lymphoma [49]. In clini-
cal studies comparing it to 90Y-ibritumomab
tiuxetan, 131I-tositumomab was demonstrated
to be nearly as efficacious as 90Y-ibritumomab
tiuxetan, but with a significantly less severe
decline in a patient’s platelet counts [49]. As
these two drugs were approved between 2002
and 2003, it remains to be seen if more prom-
ising therapies using this approach will make
it to the clinic in the near future.
concludinG reMArKS
Recent promising clinical trials justify
hopes that immunotherapy could become a
keystone of future cancer treatments. Never-
theless, there can be no doubt that much work
lies ahead for immunologists to optimize the
existing approaches and also to assess new
strategies in this growing field. Future re-
search should, for instance, allow predicting
377 Dimberu and Leonhardt: Cancer immunotherapywhich patient populations are likely to re-
spond best to which kind of therapy. With this
information, treatment protocols may become
more specifically tailored to individual pa-
tient groups. Moreover, it is necessary that we
better understand why some vaccines work
better than others, which route and particular
protocol of vaccine delivery is the most effi-
cient, and which combinations of therapies
might synergize most effectively. Unfortu-
nately in the past, cancer has proven an ever-
creative disease, often eventually overcoming
natural or induced immune responses. Thus,
better understanding how tumors evade im-
mune  attack  may  lead  to  novel  therapies
against which cancers can mount less or no
resistance. For some immunotherapies, like
ACT, it will also be crucial to make them
available for larger patient groups. Hence,
even though the list of future challenges is
long, current progress in the field is already
impressive. And notably, this progress coin-
cides with successes in other areas of cancer
therapies, for instance the treatment with ki-
nase  inhibitors  like  Gleevecﾮ [50]  or  the
BRAF inhibitor PLX4032 [51]. Already, re-
searchers  are  trying  to  integrate  these
achievements into powerful novel therapies.
Bristol-Myers Squibb and Roche recently an-
nounced a clinical collaboration in order to
assess the potential of combination therapy
using  PLX4032  and  ipilimumab  against
melanoma. And this is only one of many cur-
rent trials designed to discover possible syn-
ergies  between  either  two  or  more
simultaneously applied immunotherapies or
testing the integration of immunotherapy with
standard approaches. Driven by promising
preliminary data, these combination treat-
ments are getting more and more attention by
oncologists. In this context, it is interesting to
note that it was the combination of individu-
ally insufficient drugs that turned HIV infec-
tion from an invariably fatal disease into a
condition that is controllable in the long-term
in most patients [52]. Perhaps future progress
can make cancer a similarly manageable dis-
ease for many. 
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